Time-dependent effects of histone deacetylase inhibition in sepsis-associated acute kidney injury
Authors:
Open Access
- 7 February 2020
- journal article
- research article
- Published by Springer Nature in Intensive Care Medicine Experimental
- Vol. 8 (1) , 1-14
Abstract
Background: Sepsis, a dysregulated host response to infection with results in organ dysfunction, has been a major challenge to the development of effective therapeutics. Sepsis-associated acute kidney injury (S-AKI) results in a 3–5-fold increase in the risk of hospital mortality compared to sepsis alone. The development of therapies to reverse S-AKI could therefore significantly affect sepsis outcomes. However, the translation of therapies from preclinical studies into humans requires model systems that recapitulate clinical scenarios and the development of renal fibrosis indicative of the transition from acute to chronic kidney disease. Results: Here we characterized a murine model of S-AKI induced by abdominal sepsis developing into a chronic phenotype. We applied a small molecule histone deacetylase-8 inhibitor, UPHD186, and found that early treatment, beginning at 48 h post-sepsis, worsened renal outcome accompanied by decreasing mononuclear cell infiltration in the kidney, skewing cells into a pro-inflammatory phenotype, and increased pro-fibrotic gene expression, while delayed treatment, beginning at 96 h post-sepsis, after the acute inflammation in the kidney had subsided, resulted in improved survival and kidney histology presumably through promoting proliferation and inhibiting fibrosis. Conclusions: These findings not only present a clinically relevant S-AKI model, but also introduce a timing dimension into S-AKI therapeutic interventions that delayed treatment with UPHD186 may enhance renal histologic repair. Our results provide novel insights into successful repair of kidney injury and sepsis therapy.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK069403, R01DK112652)
- National Institutes of Health (P30DK079307)
- National Center for Research Resources (1S10RR028478-01)
This publication has 55 references indexed in Scilit:
- HDAC inhibitors in experimental liver and kidney fibrosisFibrogenesis & Tissue Repair, 2013
- Does AKI Truly Lead to CKD?Journal of the American Society of Nephrology, 2012
- The Renal Mononuclear Phagocytic SystemJournal of the American Society of Nephrology, 2012
- Histone deacetylase 3 is an epigenomic brake in macrophage alternative activationGenes & Development, 2011
- Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infectionBlood, 2011
- Histone Deacetylase: A Potential Therapeutic Target for Fibrotic DisordersThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Inhibition of Histone Deacetylase Expands the Renal Progenitor Cell PopulationJournal of the American Society of Nephrology, 2010
- Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathyAmerican Journal of Physiology-Renal Physiology, 2009
- The many roles of histone deacetylases in development and physiology: implications for disease and therapyNature Reviews Genetics, 2009
- Immunodesign of experimental sepsis by cecal ligation and punctureNature Protocols, 2008